{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:46:51Z","timestamp":1775152011171,"version":"3.50.1"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T00:00:00Z","timestamp":1470614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0160341","type":"journal-article","created":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T13:36:45Z","timestamp":1470663405000},"page":"e0160341","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects"],"prefix":"10.1371","volume":"11","author":[{"given":"Johannes S.","family":"Gach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gorlani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel Y.","family":"Dotsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C.","family":"Becerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chase T. M.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baiba","family":"Berzins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip L.","family":"Felgner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald N.","family":"Forthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven G.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J.","family":"Wilkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph P.","family":"Casazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Koup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Autran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad J.","family":"Achenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,8,8]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"e1001418","DOI":"10.1371\/journal.pmed.1001418","article-title":"Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies","volume":"10","author":"LF Johnson","year":"2013","journal-title":"PLoS Med"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QCO.0b013e32835ba6b1","article-title":"Life expectancy living with HIV: recent estimates and future implications","volume":"26","author":"F Nakagawa","year":"2013","journal-title":"Curr Opin Infect Dis"},{"issue":"9903","key":"ref3","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0140-6736(13)61998-4","article-title":"Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?","volume":"382","author":"MS Cohen","year":"2013","journal-title":"Lancet"},{"issue":"9903","key":"ref4","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIV infection as a chronic disease","volume":"382","author":"SG Deeks","year":"2013","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fimmu.2014.00417","article-title":"Challenges in HIV Vaccine Research for Treatment and Prevention","volume":"5","author":"B Ensoli","year":"2014","journal-title":"Front Immunol"},{"issue":"22","key":"ref6","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"SM Hammer","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"e10555","DOI":"10.1371\/journal.pone.0010555","article-title":"Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute\/early HIV-1 infection","volume":"5","author":"ES Rosenberg","year":"2010","journal-title":"PLoS One"},{"issue":"20","key":"ref8","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1016\/j.vaccine.2007.02.050","article-title":"Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine","volume":"25","author":"AT Catanzaro","year":"2007","journal-title":"Vaccine"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"e13579","DOI":"10.1371\/journal.pone.0013579","article-title":"Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)","volume":"5","author":"L Peiperl","year":"2010","journal-title":"PLoS One"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"e9015","DOI":"10.1371\/journal.pone.0009015","article-title":"Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses","volume":"5","author":"RA Koup","year":"2010","journal-title":"PLoS One"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"e21225","DOI":"10.1371\/journal.pone.0021225","article-title":"A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)","volume":"6","author":"GJ Churchyard","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1084\/jem.20072681","article-title":"The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?","volume":"205","author":"RP Sekaly","year":"2008","journal-title":"J Exp Med"},{"issue":"14","key":"ref13","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"BF Haynes","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ni.2264","article-title":"Lessons learned from HIV-1 vaccine trials: new priorities and directions","volume":"13","author":"AJ McMichael","year":"2012","journal-title":"Nat Immunol"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/JVI.03230-13","article-title":"Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity","volume":"88","author":"M Veillette","year":"2014","journal-title":"J Virol"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.4049\/jimmunol.1102756","article-title":"The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope","volume":"188","author":"MS de Souza","year":"2012","journal-title":"J Immunol"},{"issue":"23","key":"ref17","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"S Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/QAD.0000000000000523","article-title":"The role of HIV-specific antibody-dependent cellular cytotoxicity in HIV prevention and the influence of the HIV-1 Vpu protein","volume":"29","author":"M Kramski","year":"2015","journal-title":"AIDS"},{"issue":"14","key":"ref19","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1128\/JVI.00171-11","article-title":"An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum","volume":"85","author":"G Ferrari","year":"2011","journal-title":"J Virol"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/infdis\/jit098","article-title":"Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire","volume":"207","author":"JP Casazza","year":"2013","journal-title":"J Infect Dis"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/S2352-3018(15)00026-0","article-title":"Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial","volume":"2","author":"CJ Achenbach","year":"2015","journal-title":"Lancet HIV"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1086\/650299","article-title":"A phase 1\/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)","volume":"201","author":"H Kibuuka","year":"2010","journal-title":"J Infect Dis"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"e0125581","DOI":"10.1371\/journal.pone.0125581","article-title":"A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens","volume":"10","author":"EY Dotsey","year":"2015","journal-title":"PLoS One"},{"issue":"21","key":"ref24","doi-asserted-by":"crossref","first-page":"8575","DOI":"10.1073\/pnas.86.21.8575","article-title":"Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus","volume":"86","author":"C Cheng-Mayer","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"ref25","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1089\/aid.1998.14.1129","article-title":"Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication","volume":"14","author":"L Stamatatos","year":"1998","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1089\/08892220050058407","article-title":"Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates","volume":"16","author":"L Stamatatos","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.vaccine.2009.10.028","article-title":"Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection","volume":"28","author":"G Sellhorn","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"e85371","DOI":"10.1371\/journal.pone.0085371","article-title":"HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study","volume":"9","author":"JS Gach","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"ref29","doi-asserted-by":"crossref","first-page":"e72054","DOI":"10.1371\/journal.pone.0072054","article-title":"A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1","volume":"8","author":"JS Gach","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1074\/jbc.M109.058792","article-title":"Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1","volume":"285","author":"JS Gach","year":"2010","journal-title":"J Biol Chem"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1593\/neo.81578","article-title":"Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors","volume":"11","author":"EM Bruckheimer","year":"2009","journal-title":"Neoplasia"},{"issue":"41","key":"ref32","doi-asserted-by":"crossref","first-page":"12675","DOI":"10.1073\/pnas.1509090112","article-title":"Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants","volume":"112","author":"A Loos","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref33","article-title":"Introduction of germline residues improves the stability of anti-HIV mAb 2G12-IgM","author":"V Chromikova","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"ref34","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1086\/500410","article-title":"Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection","volume":"42","author":"S Kassutto","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/QAI.0b013e3180654836","article-title":"Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy","volume":"45","author":"LE Jones","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"ref36","doi-asserted-by":"crossref","first-page":"e110749","DOI":"10.1371\/journal.pone.0110749","article-title":"Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients","volume":"9","author":"LM Hofstra","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"ref37","doi-asserted-by":"crossref","first-page":"e106240","DOI":"10.1371\/journal.pone.0106240","article-title":"Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial","volume":"9","author":"UN Sarwar","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1128\/JVI.06091-11","article-title":"Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity","volume":"86","author":"Z Euler","year":"2012","journal-title":"J Virol"},{"issue":"5","key":"ref39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/COH.0b013e32832f4a4d","article-title":"Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?","volume":"4","author":"DC Montefiori","year":"2009","journal-title":"Current Opinion in Hiv and Aids"},{"issue":"6","key":"ref40","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ni.3158","article-title":"Antibody responses to envelope glycoproteins in HIV-1 infection","volume":"16","author":"DR Burton","year":"2015","journal-title":"Nature Immunology"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00063030-200923030-00001","article-title":"Progress on the Induction of Neutralizing Antibodies Against HIV Type 1 (HIV-1)","volume":"23","author":"M Vaine","year":"2009","journal-title":"Biodrugs"},{"issue":"2","key":"ref42","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrmicro1819","article-title":"The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus","volume":"6","author":"GBK Hedestam","year":"2008","journal-title":"Nature Reviews Microbiology"},{"key":"ref43","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.7254.1","article-title":"Harnessing the protective potential of HIV-1 neutralizing antibodies","volume":"5","author":"SA Smith","year":"2016","journal-title":"F1000Res"},{"issue":"2","key":"ref44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1084\/jem.20121827","article-title":"Neutralizing antibodies to HIV-1 induced by immunization","volume":"210","author":"LE McCoy","year":"2013","journal-title":"J Exp Med"},{"issue":"5","key":"ref45","doi-asserted-by":"crossref","first-page":"e1002721","DOI":"10.1371\/journal.ppat.1002721","article-title":"Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape","volume":"8","author":"KJ Bar","year":"2012","journal-title":"PLoS Pathog"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1742-4690-9-76","article-title":"HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection","volume":"9","author":"D Basu","year":"2012","journal-title":"Retrovirology"},{"issue":"1","key":"ref47","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1128\/JVI.77.1.353-365.2003","article-title":"Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies","volume":"77","author":"P Poignard","year":"2003","journal-title":"Journal of Virology"},{"issue":"5","key":"ref48","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1128\/JVI.80.5.2515-2528.2006","article-title":"Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1","volume":"80","author":"PL Moore","year":"2006","journal-title":"Journal of Virology"},{"issue":"5","key":"ref49","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nbt.2197","article-title":"B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study","volume":"30","author":"BF Haynes","year":"2012","journal-title":"Nat Biotechnol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1146\/annurev-immunol-032712-095916","article-title":"Broadly Neutralizing Antiviral Antibodies","volume":"31","author":"D Corti","year":"2013","journal-title":"Annual Review of Immunology, Vol 31"},{"issue":"21","key":"ref51","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1128\/JVI.01023-12","article-title":"Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family","volume":"86","author":"M Bonsignori","year":"2012","journal-title":"J Virol"},{"issue":"8","key":"ref52","doi-asserted-by":"crossref","first-page":"e1002890","DOI":"10.1371\/journal.ppat.1002890","article-title":"ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge","volume":"8","author":"MD Alpert","year":"2012","journal-title":"PLoS Pathog"},{"issue":"1","key":"ref53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/vaccines2010015","article-title":"Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates","volume":"2","author":"GD Tomaras","year":"2014","journal-title":"Vaccines (Basel)"},{"issue":"7158","key":"ref54","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"AJ Hessell","year":"2007","journal-title":"Nature"},{"key":"ref55","first-page":"289","article-title":"Which Antibody Functions are Important for an HIV Vaccine?","volume":"5","author":"B Su","year":"2014","journal-title":"Front Immunol"},{"issue":"16","key":"ref56","doi-asserted-by":"crossref","first-page":"8672","DOI":"10.1128\/JVI.00287-12","article-title":"Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding","volume":"86","author":"A Smalls-Mantey","year":"2012","journal-title":"J Virol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0160341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:08:52Z","timestamp":1588968532000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0160341"}},"subtitle":[],"editor":[{"given":"Alan","family":"Landay","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,8]]},"references-count":56,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0160341","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,8]]}}}